Immunome (NASDAQ:IMNM – Get Free Report) and Nutra Pharma (OTCMKTS:NPHC – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.
Profitability
This table compares Immunome and Nutra Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunome | N/A | -51.31% | -47.62% |
| Nutra Pharma | -364.90% | N/A | -159.08% |
Valuation and Earnings
This table compares Immunome and Nutra Pharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immunome | $6.94 million | 456.75 | -$212.39 million | ($2.38) | -11.76 |
| Nutra Pharma | $380,000.00 | 1.88 | -$2.05 million | N/A | N/A |
Nutra Pharma has lower revenue, but higher earnings than Immunome.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Immunome and Nutra Pharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunome | 1 | 0 | 12 | 0 | 2.85 |
| Nutra Pharma | 0 | 0 | 0 | 0 | 0.00 |
Immunome presently has a consensus price target of $34.64, suggesting a potential upside of 23.75%. Given Immunome’s stronger consensus rating and higher possible upside, research analysts clearly believe Immunome is more favorable than Nutra Pharma.
Insider and Institutional Ownership
44.6% of Immunome shares are owned by institutional investors. 7.2% of Immunome shares are owned by company insiders. Comparatively, 61.5% of Nutra Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Immunome has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Comparatively, Nutra Pharma has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.
Summary
Immunome beats Nutra Pharma on 9 of the 12 factors compared between the two stocks.
About Immunome
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
About Nutra Pharma
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
